NEW YORK, NY--(Marketwire - July 01, 2010) - AntriaBio President Ted Kalem presented at the OneMedForum: Emerging Company Finance Conference on Wednesday, June 30th. The conference was held at the Roosevelt Hotel in New York City. Mr. Kalem also serves as President of BRIC Biotech, an emerging growth fund that invests in healthcare and life science companies, including AntriaBio.
Kalem provided an overview of AntriaBio's clinical development programs and updated investors on financing activities related to its diabetes product candidate, AB101.
AB101 is a once-a-week injectable basal insulin that is currently in preclinical development. AB101 is administered by subcutaneous injection and targets patients with type 1 and type 2 diabetes who require basal insulin for the control of hyperglycemia. The formulation has been designed to release insulin slowly and uniformly over a period of approximately one week with no initial burst of drug.
"To our knowledge, there are no other technologies in development that offer the potential for once-a-week dosing. We believe AB101 represents a highly differentiated and truly unique product opportunity in the large and rapidly growing diabetes market," said Kalem.
About AntriaBio
AntriaBio's lead diabetes product candidate, AB101, is a once-a-week injectable basal insulin that is currently in preclinical development. AB101 is administered by subcutaneous injection and targets patients with type 1 and type 2 diabetes who require basal insulin for the control of hyperglycemia.
Visit: antriabio.com
About BRIC Biotech, LLC
BRIC Biotech, an emerging growth fund that invests in healthcare and life science companies, brings platform and enabling technologies, medical devices, instrumentation, novel therapeutics and healthcare services businesses, to new markets globally.
BRIC Biotech is focused on the emerging markets in Brazil, Russia, India and China and its investments and expertise are balanced across all stages of company development including Venture Capital, Growth Equity and Public Markets. BRIC Biotech seeks long-term involvement with investments and provides much more than financial backing.
Visit: http://bricbiotech.com
